Document:

Prepared and filed by St Ives Financial

Exhibit 10.2

CELERA DIAGNOSTICS

REORGANIZATION

AGREEMENT

EFFECTIVE AS OF JANUARY 1, 2006

CELERA DIAGNOSTICS REORGANIZATION AGREEMENT

     This CELERA DIAGNOSTICS REORGANIZATION AGREEMENT (this “Agreement”) is dated as of the 22nd day of April, 2006, and effective as of January 1, 2006 (the “Effective Date”), and is by and among Applera Corporation (“Applera”), the Applied Biosystems Group of Applera (“Applied Biosystems”), the Celera Genomics Group of Applera (“Celera Genomics”), Foster City Holdings, LLC (the “AB LLC”), and Rockville Holdings, LLC (the “CRA LLC”).

RECITALS

     CDx Joint Venture Reorganization

     WHEREAS, Applied Biosystems (and its wholly-owned subsidiary AB LLC) and Celera Genomics (and its wholly-owned subsidiary CRA LLC) are parties to a Joint Venture Agreement dated as of April 1, 2001, as amended (the “JV Agreement”), pursuant to which Applied Biosystems and Celera Genomics formed Celera Diagnostics, LLC (“CDx”), as a joint venture between them operating in the field of human in vitro diagnostics (as more particularly defined therein, the “HIVD Field”);

     WHEREAS, pursuant to and as contemplated by the JV Agreement, as of the Effective Date: (i) Applied Biosystems owned a 50% membership interest in CDx, designated as a Class A Membership Interest, indirectly through AB LLC, and (ii) Celera Genomics owned a 50% membership interest in CDx, designated as a Class B Membership Interest, indirectly through CRA LLC;

     WHEREAS, since its formation, CDx has developed its business, and the parties believe that Applied Biosystems’ and Celera Genomics’ interests in CDx have become increasingly valuable; 

     WHEREAS, as the CDx business has developed, CDx and Celera Genomics, with the express consent of Applied Biosystems, have identified and capitalized on various synergies between their two businesses, including the use of their respective scientific research for both therapeutic and diagnostic development, and their joint use of the expertise of key personnel; and Celera Genomics and CDx believe that the continued growth of their businesses can benefit from these types of synergies, but that these synergies would be optimized if the operations of the two business were combined;

     WHEREAS, despite the development of the CDx business, the parties believe that the full value of that business has not been realized or reflected in the stock values of either Applied Biosystems or Celera Genomics and that Applera and all of its stockholders could benefit from a reorganization of CDx whereby Celera Genomics and CDx would operate as a single business unit and Applied Biosystems’ value in CDx would be translated into a form that would better serve its ongoing operations;

     WHEREAS, in light of the foregoing, it has been proposed that the JV Agreement be terminated and Applied Biosystems transfer its interest in CDx to Celera Genomics, effectively combining the CDx business with and into the Celera Genomics business (the “CRA/CDx Combination”) and, subject to the provisions of this Agreement, reallocating the HIVD Field between Applied Biosystems and Celera Genomics in a manner designed to optimize market opportunities and resources among each group;

     WHEREAS, such reorganization has been accompanied by an exchange of consideration representing fair value for the transferred interest consisting of the following (collectively, the “Transfer Consideration”):

		
•	
the NOL Benefit resulting from the termination of the JV Agreement, which is described below in these recitals;

		
•	
the Clinical Continuum Arrangement, which is described below in these recitals and the terms and conditions of which are set forth in Article II below and the attached Annex to Article II;

		
•	
the Reagent Development and Manufacturing Project, which is described below in these recitals; 

		
•	
the M&D Royalty Termination, which is described below in these recitals and the terms and conditions of which are set forth in Article III below;

		
•	
the Transfer Price Increase, which is described below in these recitals; and

		
•	
the Cash Payment described in Article IV below;

     NOL Benefit

     WHEREAS, pursuant to the terms of the JV Agreement, Applied Biosystems agreed to reimburse Celera Genomics for any tax benefits resulting from losses generated by the CDx business or any other tax benefits generated by CDx to the extent such benefits are utilized by Applied Biosystems;

     WHEREAS, because of the termination of the JV Agreement as contemplated herein, Applied Biosystems will no longer be subject to that reimbursement obligation and will therefore receive an additional economic benefit from the termination of the JV Agreement (the “NOL Benefit”);

     Clinical Continuum Arrangement

     WHEREAS, the evolution of genomics and proteomics research is causing changes in the market conditions for research tools, the focus of the Applied Biosystems business, and diagnostic products, the focus of the CDx business; and these changes in market conditions are causing a convergence of the research and diagnostic markets and a linkage between research platforms and diagnostic applications, as customers are seeking to rapidly migrate discoveries made on research platforms into new corresponding diagnostic products and services;

     WHEREAS, Applera believes that these customers will increasingly need access

- 2 -

to technology platforms that seamlessly support their efforts along the pathway (referred to herein as the “Clinical Continuum”) from broad scale discovery, through replication, medical utility studies, and ultimately commercialization of new diagnostics;

     WHEREAS, Applera believes that it can best respond to this market opportunity and address emerging competitive threats by establishing an arrangement between Applied Biosystems and CDx to maximize effective coverage of the entire Clinical Continuum and minimize duplicate use of internal resources, thereby leveraging (i) Applied Biosystems’ expertise and success in developing, manufacturing, and marketing technology platforms and its broad installed base of customers with (ii) CDx’s diagnostics research and development efforts, including its expertise in diagnostic assay development, manufacturing, and marketing (as more particularly set forth in the Annex to Article II attached hereto, the
“Clinical Continuum Arrangement”);

     WHEREAS, pursuant to the Clinical Continuum Arrangement, Applied Biosystems would be permitted to engage in certain business activities within the HIVD Field, previously exclusive to the CDx business;

     Reagent Development and Manufacturing Project

     WHEREAS, Applied Biosystems is currently purchasing from third parties certain reagents that it sells to customers and wishes to develop its own internal source of similar reagents;

     WHEREAS, Applied Biosystems believes it will be able to recognize additional income and provide more differentiated products to customers with such internally supplied reagents;

     WHEREAS, CDx has the personnel with relevant experience to assist Applied Biosystems in developing and manufacturing such reagents, and Applera believes that such assistance would increase the certainty and decrease the time period for Applied Biosystems’ successful development of such capability as compared to the engagement of third parties for such purpose;

     WHEREAS, in connection with the transactions contemplated hereby and in light of the foregoing considerations, Celera Genomics has agreed that CDx will assist Applied Biosystems in developing and manufacturing reagents (the “Reagent Development and Manufacturing Project”);

     Marketing and Distribution Agreement

     WHEREAS, Applied Biosystems and Celera Genomics are also parties to an Amended and Restated Marketing and Distribution Agreement, originally dated as of April 1, 2002, as amended (the “Marketing and Distribution Agreement”);

     WHEREAS, pursuant to the Marketing and Distribution Agreement, Applied

- 3 -

Biosystems obtained exclusive rights to some of Celera Genomics’ human genomic and other biological and medical information in exchange for Applied Biosystems’ agreement to pay royalties to Celera Genomics based on revenues generated by sales of some Applied Biosystems products;

     WHEREAS, in light of the proposed CRA/CDx Combination, it has been further proposed that Applied Biosystems’ royalty payment obligations under the Marketing and Distribution Agreement be terminated but that the value of the terminated royalties be included in the consideration to be paid to Applied Biosystems for the CRA/CDx Combination (the “M&D Royalty Termination”);

     WHEREAS, Applera believes that this proposed termination of royalty payments serves the interest of Applera and its stockholders by simplifying the ongoing relationship between the two groups and therefore increasing transparency of the financial relationship between the two groups;

     Transfer Price Increase

     WHEREAS, Applied Biosystems currently supplies certain consumables and other products to CDx on a cost basis rather than the price at which such products would otherwise be sold to a third-party in a commercial transaction;

     WHEREAS, in connection with the CRA/CDx combination, and in light of the fact that Applied Biosystems will no longer have an interest in the CDx business, Applied Biosystems and Celera Genomics have agreed to increase the inter-group transfer price for such products (the “Transfer Price Increase”); and 

     Board Approval of Transactions

     WHEREAS, in connection with its consideration of the CRA/CDx Combination and the related transactions described above, the Applera Board of Directors (the “Applera Board”) considered numerous factors and received advice from several independent advisors, including analyses of the value of Applied Biosystems’ interest in CDx as well as the value of the other components of the transactions described herein;

     WHEREAS, the Applera Board reviewed and considered an opinion of an independent investment banking firm regarding the fair value of (i) Applied Biosystems’ interest in CDx and (ii) the Transfer Consideration; 

     WHEREAS, based on an evaluation of all relevant factors, including the opinion described above, the Applera Board determined that the proposed transactions are fair to and in the best interest of Applera and its stockholders and approved the proposed transactions; and 

     WHEREAS, pursuant to the approval of the Applera Board, the parties have implemented the transactions described above with effect from the Effective Date, and

- 4 -

the parties desire to enter into this Agreement to memorialize the terms and conditions of such transactions.

     NOW, THEREFORE, the parties hereto agree as follows, effective as of the Effective Date:

ARTICLE I.

TERMINATION OF JV AGREEMENT

AND TRANSFER OF AB’S INTEREST

     The parties agree that the JV Agreement is terminated effective as of the Effective Date.  Applied Biosystems hereby agrees to and confirms the transfer, effective as of the Effective Date, all of its Class A Membership Interest in CDx to Celera Genomics, without any representation or warranty, except that Celera Genomics has acquired such interest free and clear of any liens, encumbrances, or claims arising through Applied Biosystems.  This transfer has been accomplished by a reallocation of its interest in ABI LLC on the Applera books and records to Celera Genomics.  From and after the Effective Date, all of the CDx assets, liabilities, and business shall be attributed to Celera Genomics and, except as specifically
set forth herein, Celera Genomics’ principal business shall be deemed expanded to include the HIVD Field, which, as reallocated between Applied Biosystems and Celera Genomics, is described in the attached Annex to Article I.

ARTICLE II.

CLINCIAL CONTINUUM ARRANGEMENT

	
     2.1     General; Scope of Arrangement.  The attached Annex to Article II sets forth the terms and conditions of the Clinical Continuum Arrangement.  
	 

	
     2.2     Management of Relationship; Designated Representative and Day-to-Day Interaction.  To facilitate the effectiveness of the Clinical Continuum Arrangement and to facilitate the day-to-day operation of the arrangement, Applied Biosystems and Celera Genomics will establish a set of operating principles setting forth processes and procedures for the two businesses to work together and cooperate on matters relating to:  research and development; manufacturing; marketing; sales; service; regulatory compliance; general strategy and new business opportunities; and general Clinical Continuum Arrangement oversight (the “Operating Principles”).  The Operating Principles shall also set
forth matters that require joint consultation, if any, and procedures for the parties to address and resolve actual or potential issues that may arise from time to time, in all cases consistent with Applera’s tracking stock principles (including the role of the Inter-Group Policy Committee, which is defined in Section 5.2 below).  For purposes of the Operating Principles, both of Applied Biosystems and Celera Genomics shall designate an individual as the designated representative of the group to serve as the primary contact for matters relating to the arrangement (the

- 5 -

	
“Designated Representative”).  The Designated Representative of a group shall either be the President of the group or another senior management employee chosen by the President of the
group.

ARTICLE III.

M&D ROYALTY TERMINATION AND OTHER AMENDMENTS TO THE

MARKETING AND DISTRIBUTION AGREEMENT

	
     3.1     Termination of Royalty and Other Inapplicable Provisions.  Effective as of the Effective Date, the text of each of the follow sections of Annex A to the Marketing and Distribution Agreement is amended and restated in its entirety to read “[Intentionally Omitted]”:
	 

		
(a)	
Section 2.1, “Cooperation between AB and Celera.”
	 	 	 

		
(b)	
Section 2.2, “Online/Information Business Personnel.”
	 	 	 

		
(c)	
Section 2.3, “Operating Procedures.”
	 	 	 

		
(d)	
Section 4.1, “Royalty to Celera for Covered Products.”
	 	 	 

		
(e)	
Section 4.2, “Reimbursement of Costs.”
	 	 	 

		
(f)	
Section 5, “Shared Services.”
	 	 	 

		
(g)	
Section 6.3, “Celera Diagnostics.”
	 	 	 

	
     3.2     Status of Marketing and Distribution Agreement.  Except as set forth in Section 3.1 above, the Marketing and Distribution Agreement remains in full effect without amendment.  Also, notwithstanding the amendments provided for in Section 3.1 above, Applied Biosystems and/or Celera Genomics shall remain responsible for performing or paying any obligations or liabilities under the amended provisions that were outstanding as of the Effective Date.

ARTICLE IV.

CASH PAYMENT

     Celera Genomics shall pay to Applied Biosystems the amount of $30,000,000 in cash (the “Cash Payment”).  The Cash Payment has been effected by way of a book entry reallocation of Applera cash from Celera Genomics to Applied Biosystems as of the Effective Date.

- 6 -

ARTICLE V.

MISCELLANEOUS

	
     5.1     Further Assurances.  The parties agree to cooperate and take all action as is reasonably necessary to give full effect to the transactions described herein.
	 
	
     5.2     Interpretation of Agreement; Resolution of Disputes.  All questions, concerns, disputes, or other issues that may arise relating to this Agreement, including its interpretation, shall be subject to the same procedures and processes currently used to resolve issues between Applied Biosystems and Celera Genomics within Applera.  These procedures and processes include the Applera Inter-Group Policy Committee (the “Inter-Group Policy Committee,” which term includes any processes or procedures for resolutions of issues between Applied Biosystems and Celera Genomics as may be applicable from time to time, and any successor committees, processes, or procedures).
	 
	
     5.3     Role of Applera Board.  
	 
	
     (a)     Any matter relating to this Agreement which cannot be resolved or addressed by the Inter-Group Policy Committee pursuant to Section 5.2 above may be referred by the Applera Chief Executive Officer to the Applera Board, and any resulting determination by the Applera Board shall be binding on the parties.  Notwithstanding anything to the contrary contained herein, all matters relating to this Agreement shall at all times remain within the purview of the Applera Board, which shall have the authority to review such matters on its own initiative.
	 
	
     (b)     Without limitation of the foregoing clause (a), the Applera Board must approve any matter that requires such approval pursuant to the Company’s tracking stock principles and/or its Certificate of Incorporation.  For example, as a result of the operation and evolution of the arrangements contemplated herein, the parties may seek to modify, in their mutual interest, (i) the HIVD Field or (ii) the extent to which one or both of Applied Biosystems or Celera Genomics may be permitted to operate in the primary field of business of the other group (including the extent to which Applied Biosystems may operate in the HIVD Field).  Such modifications could, for example, become necessary or advisable:  to
most effectively pursue existing corporate opportunities, either because of changing market conditions for Clinical Continuum products and services or because of knowledge learned from the operation of the Clinical Continuum Arrangement; or to allocate new business opportunities.  However, if material those modifications will require approval of the Applera Board.
	 
	
     5.4     Amendments and Waivers.  Subject to any approval of the Applera Board required under Section 5.3 of this Agreement, the terms and conditions contained in this Agreement, including the description of the HIVD Field and the extent to which Applied Biosystems may operate in the HIVD Field, may be amended, and the conduct of the parties may deviate from such terms and conditions, with the approval of the Inter-Group Policy Committee; provided, however, that any amendment to this Agreement, upon

- 7 -

	
receiving the necessary
approval, shall be in a written instrument signed by (a) Applied Biosystems,
(b) Celera Genomics, and (c) the CEO.
	 
	
     5.5     Transaction Expenses.  All out-of-pocket costs and expenses incurred by Applera or its affiliates in connection with the negotiation and implementation of the arrangements provided for herein shall be borne equally by Applied Biosystems and Celera Genomics.

[Remainder of Page Intentionally Left Blank]

- 8 -

          IN WITNESS WHEREOF, the parties agree to the foregoing as of the date first written above.
  		APPLERA CORPORATION

By: /s/ Tony L. White
             Name:  Tony L. White 

             Title:  Chairman, President and 

             Chief Executive Officer 

APPLIED BIOSYSTEMS GROUP OF 

APPLERA CORPORATION

By: /s/ Catherine M. Burzik
             Name:  Catherine M. Burzik

             Title: President

CELERA GENOMICS GROUP OF 

APPLERA CORPORATION

By: /s/ Kathy
Ordoñez
             Name:  Kathy Ordoñez

       Title:  President

FOSTER CITY HOLDINGS, LLC

By:  Applera Corporation, as the sole member 

of Foster City Holdings, LLC

By: /s/ Catherine M. Burzik
       Name:  Catherine M. Burzik
       Title:  President

ROCKVILLE HOLDINGS, LLC

By:  Applera Corporation, as the sole member 

of Rockville Holdings, LLC

By: /s/ Kathy
Ordoñez
       Name:  Kathy Ordoñez
       Title:  President

- 9 -

ANNEX TO ARTICLE I

DESCRIPTION OF HIVD FIELD

     This Annex sets forth a description of the HIVD Field.  Capitalized terms used in this Annex shall have the meanings assigned thereto in the Agreement or as set forth below, as the case may be.

     The business of Celera Genomics will include the field of Human In Vitro Diagnostics (the HIVD Field).  The HIVD Field, which, except as set forth below, will be exclusive to Celera Genomics, comprises products, technologies, services, and/or processes for use in the measurement, observation, or determination of attributes, characteristics, diseases, traits, or other conditions:

		•	for medical management of a human being; and/or

		
•	
for quality control or testing of human blood or tissue for transfusion or blood banking, bone marrow transplantation or banking, or tissue typing for transplantation.

     Examples of activities in the HIVD Field:

		
•	
Development, manufacture, or sale of anything labeled for in vitro diagnostic use or any testing products labeled for investigational use;

		
•	
Development, manufacture, or sale of products designated as Analyte Specific Reagents (ASRs) by FDA or corresponding reagent products in foreign regulatory jurisdictions and general purpose reagents (GPRs) that are specifically sold for use with ASRs or such reagent products;

		
•	
Development or sale of software products for the interpretation of data to provide an HIVD clinical test result;

		
•	
Development, manufacture, or sale of products that convey amplification, sequencing, or other patent rights in the HIVD Field, or products that are designated specifically for use with products that convey amplification, sequencing, or other patent rights in the HIVD Field;

		
•	
Genetic testing for sample tracking in a clinical laboratory;

		
•	
Sale of any in vitro testing products regulated by the FDA, including products claimed to be produced under Quality System Regulation to be sold to IVD companies or clinical testing laboratories;

		
•	
In- and out-licensing or other transfer of patents, technology, or know-how for HIVD use (including any accompanying contract manufacture of custom reagents for specific diagnostic customers’ homebrew testing, whether or not the reagents are produced under Quality System Regulation);

		
•	
Development, manufacture, or sale of, or providing
service and support for, systems (reagents, components and/or instruments) developed
and

		 	
manufactured for HIVD use or developed specifically
for use with ASRs (or their counterparts outside the US); and
		
•	
Provision of HIVD testing services.

     Examples of activities not in the HIVD Field:

		
•	
Development, manufacture, or sale of products or services for basic and applied research, including clinical research where the medical management of a patient is not involved, unless the product or service is regulated as an in vitro diagnostic test or ASR by the FDA or its foreign counterparts;

		
•	
Development, manufacture, or sale of products or services for quality assurance and quality control, including testing to determine conformance with specifications, purity and batch-to-batch consistency, but excluding human plasma or tissue-derived samples for the pharmaceutical industry;

		
•	
Testing of environmental samples, including the detection of organisms, where the medical management of a human is not involved;

		
•	
Identity testing applications for forensic purposes or determination of paternity, excluding genotyping or other identification testing for medical management of a human being or sample tracking in a clinical laboratory;

		
•	
In vitro diagnostic testing of non-human (plant or animal) samples, including animal breeding, pedigree determination, or gender determination;

		
•	
Testing for the agricultural or food industries, including the identification of genetically modified organisms (GMOs) for these industries; 

		
•	
Sale or service of general purpose (“open”) instrument systems or general purpose reagents, including enzymes, unless specifically sold for use with ASRs or other products regulated by the FDA or its foreign counterparts;

		
•	
Sale of non-exclusive information products and services not regulated by FDA (such as the Celera Discovery System) to any customers, including those customers operating in the HIVD Field;

		
•	
Sale of anything labeled for therapeutic or prophylactic use;

		
•	
Sale of products or services that convey therapeutic or research patent rights; 

		
•	
In- and out- licensing or other transfer of patents, technology or know-how for use in the therapeutic, research, or applied fields;

		
•	
Embryonic stem cell and recombinant cell characterization, testing, and quality control applications; and

		
•	
Epidemiology testing (the screening or testing of groups of people or populations for the study of the patterns, causes, or control of disease in groups of people) and biosecurity testing (the detection of biological or chemical agents, pathogens, microorganisms or other infectious agents in the environment, agriculture, food or water), where the medical management of a human is not involved.

Annex I – Page 2

     Notwithstanding the foregoing, Applied Biosystems:

	1.	
 may develop, manufacture (under Quality System Regulation), or sell instrument systems registered with the FDA or its foreign counterparts and associated application-specific software for use in the HIVD Field, provided, that they are sold only to end users (either directly or indirectly through distributors, marketing representatives, and the like) and Applied Biosystems’ activities do not Facilitate (as defined below) competition with Celera Genomics’ existing and planned reagent products in the HIVD Field (such products, “Competing Products”); and provided further, that Applied Biosystems’ manufacture and sale of any registered diagnostic instrument system in the HIVD Field as an OEM for resale or
placement by a third party shall be subject to (i) the requirements of the Restated Strategic Alliance Agreement among Applera Corporation, Celera Diagnostics, LLC and Abbott Laboratories for so long as it is in effect, which may restrict such activities; and (ii) thereafter, the approval of Applera Executive Committee and the provisions of Article V of the Agreement regarding the resolution of disputes.  “Facilitate” means to sell, distribute or promote a product or a service, or to partner with a third party to sell, distribute or promote a product or service, where such product or service is promoted as a Competing Product or distributed with knowledge of its use as a Competing Product.  In the case of instruments, Facilitate means distributing or loading instruments
with software, or distributing, promoting or actively assisting in the development of software for the instrument, that is specific to a Competing Product (i.e., software specific to a diagnostic application).
	 	 
	2.	
 may sell sequence-specific primers or probes, or assays containing such primers or probes for use in the HIVD Field, provided that they are not claimed to have been produced under Quality System Regulation (but they may be made under a certified quality system with traceable documentation), and the sale of these reagents does not Facilitate competition with Competing Products.
	 	 
	3.	
 has unrestricted rights to sell GPRs and instruments in all fields, including the HIVD Field, provided that such GPRs and instruments are properly labeled as such with corresponding use restrictions.

Annex I – Page 3

ANNEX TO ARTICLE II

CLINICAL CONTINUUM ARRANGEMENT

     This Annex sets forth the terms and conditions of the Clinical Continuum Arrangement between Celera Genomics and Applied Biosystems pursuant to the Agreement of which this Annex is a part.  Capitalized terms used in this Annex shall have the meanings assigned thereto in the Agreement or as set forth below, as the case may be.

Product Development and Support – Instrumentation

     Celera Genomics will provide product development support to Applied Biosystems aimed at ensuring that the diagnostic instrument systems developed by Applied Biosystems pursuant to this Clinical Continuum Arrangement are optimally suited for homebrew and diagnostic testing in the HIVD Field.  Applied Biosystems will pay Celera Genomics appropriate compensation for such services; provided, that instrument systems developed for the joint use and/or sale by Applied Biosystems and Celera Genomics will be subject to mutually acceptable economic arrangements that address the costs and expenses incurred in mutually developing such instrument systems, the terms and conditions upon which Celera Genomics will have access
to such instrument systems from Applied Biosystems, and/or other considerations deemed relevant by the parties.  Furthermore, Applied Biosystems will be the preferred supplier of instruments to the alliance under the Restated Strategic Alliance Agreement among Applera Corporation, Celera Diagnostics, LLC, and Abbott Laboratories (the “Abbott Alliance Agreement”) and will have such rights, roles, and responsibilities relating to the development of instruments for such alliance all as and to the extent set forth in the Abbott Alliance Agreement.

Product Development and Support – Assays 

     Celera Genomics will provide support and assistance to Applied Biosystems’ customers in exploring their promising discoveries as potential new diagnostic opportunities.  If an Applied Biosystems customer desires to develop and commercialize a diagnostic assay discovery in collaboration with Applera, Applied Biosystems and Celera Genomics will develop a process to evaluate the opportunity with specified timelines and response milestones on a case-by-case basis.  Celera Genomics will have the first opportunity to develop a business case for commercializing a product based on such collaboration.  If Celera Genomics declines to pursue the opportunity, it may seek to contract manufacture the assay for the customer
pursuant to appropriate compensation from Applied Biosystems or the customer.  In the event that Celera Genomics does not wish to manufacture the assay, Applied Biosystems and Celera Genomics will work together in advising such customer in regard to alternative solutions for commercialization activities.  Celera Genomics’ delivery of services pursuant to this paragraph, and also if applicable its pursuit of any opportunity pursuant to this paragraph,

will be subject to mutually acceptable economic arrangements that address the mutual costs, expenses, and/or other contributions to any such opportunity as well as any other considerations deemed relevant by the parties.

Regulatory Support

     Within Applera, Celera Genomics will have sole responsibility for all regulatory matters involving products and services that are regulated by the FDA or its foreign counterparts, including the decision-making authority on the interpretation of Quality System Regulation requirements and communication with such agencies regarding regulatory matters related to Applera business activities.  In that capacity, Celera Genomics will provide assistance to Applied Biosystems in regulatory matters in support of the development of instrument systems and associated software for registration with the FDA and its foreign counterparts.  Applied Biosystems will pay Celera Genomics appropriate and mutually acceptable compensation for
such services.

Limited License

     Applied Biosystems shall have the right to grant a limited license to Applera intellectual property to end users to use registered diagnostic instrument systems in the HIVD Field consistent with the requirements of and restrictions contained in the Agreement, including the HIVD Field and this Annex, provided that such instruments are properly labeled with corresponding use restrictions.

Economic Arrangements/Program Resources

     Any and all compensation and other economic arrangements contemplated by this Annex shall be consistent with the Applera tracking stock principles.  Such arrangements must be mutually agreed to between Applied Biosystems and Celera Genomics and approved by the Applera Executive Committee, and any disputes regarding these matters are subject to Article V of the Agreement.

     Applied Biosystems may choose to engage the services of certain dedicated employees to work closely with Celera Genomics’ R&D, Regulatory Affairs and Business Development organizations to advise and assist Applied Biosystems’ customers in exploring their promising discoveries as potential new diagnostic opportunities.  These employees will be situated at a mutually agreeable location.  Applied Biosystems will be responsible for the funding of these employees unless such funding is incorporated into the economic arrangements otherwise contemplated by this Annex.

     Consistent with Applera’s tracking stock principles, neither Applied Biosystems nor Celera Genomics may hire an employee of the other group without the consent of the affected group.

Annex II – Page 2<PAGE>

                                                                    Exhibit 10.1

                     SUPPLEMENT TO THE AMENDED AND RESTATED
                        AGREEMENT OF LIMITED PARTNERSHIP
                                       OF
                       RECKSON OPERATING PARTNERSHIP, L.P.
                          ESTABLISHING 2006 LTIP UNITS
                                       OF
                          LIMITED PARTNERSHIP INTEREST

         In accordance with Sections 4.2 and 14.1.B (2), (3) and (4) of the
Amended and Restated Agreement of Limited Partnership, dated as of June 2, 1995,
as amended on December 6, 1995, April 13, 1998, April 20, 1998, June 30, 1998,
May 24, 1999, June 2, 1999, October 13, 2000, August 7, 2003, December 27, 2004
and March 11, 2005 (the "Partnership Agreement"), the Partnership Agreement is
hereby supplemented (the "Supplement") to establish a class of units of limited
partnership interest of Reckson Operating Partnership, L.P. (the "Partnership"),
which shall be designated "2006 LTIP Units," having the rights, powers,
privileges and restrictions, qualifications and limitations as set forth below
and which shall be issued to the parties and in the amounts set forth on
SCHEDULE A hereto. Capitalized terms used and not otherwise defined herein shall
have the meanings set forth in the Partnership Agreement, including the
Supplement thereto, dated December 27, 2004, establishing LTIP Units of limited
partnership interest.

         WHEREAS, the Partnership desires to provide for equity incentives to
certain employees of the Company who provide services for the benefit of the
Partnership ("Grantees").

         WHEREAS, pursuant to Section 4.2 of the Partnership Agreement, the
Partnership is issuing 2006 LTIP Units to the Grantees with the rights, powers,
privileges and restrictions, qualifications and limitations as set forth below.

         WHEREAS, pursuant to Section 4.2 and Sections 14.1.B (2), (3) and (4)
of the Partnership Agreement, the General Partner is amending and supplementing
the Partnership Agreement to facilitate the issuance of the 2006 LTIP Units.

         NOW THEREFORE, in consideration of the mutual covenants contained
herein, and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:

SECTION 1.        Issuance of 2006 LTIP Units.

(a) Pursuant to Section 4.2 of the Partnership Agreement, the Partnership hereby
issues 207,000 Partnership Interests (the "2006 LTIP Units") to the Grantees and
in the amounts set forth on SCHEDULE A hereto. The 2006 LTIP Units shall have
the rights, powers, privileges, restrictions, qualifications and limitations
(including, but not limited to, limitations on transfer) of Limited Partners
under the Partnership Agreement, as supplemented and amended by the rights,
powers, privileges, restrictions, qualifications and limitations specified in
EXHIBIT I hereto.

(b) The admission of the Grantees as Additional Limited Partners of the
Partnership shall become effective as of the date of this Supplement, which
shall also be the date upon which the names of the Grantees are recorded on the
books and records of the Partnership, and Exhibit A to the Partnership Agreement
is amended to reflect such admission.

<PAGE>

SECTION 2.        Amendments to Partnership Agreement.

                  Pursuant to Section 14.1.B(3) of the Partnership Agreement,
the General Partner, as general partner of the Partnership and as
attorney-in-fact for its Limited Partners, hereby amends the Partnership
Agreement as follows:

                  (a) Article 1 of the Partnership Agreement is hereby amended
by inserting the following definitions in alphabetical order:

                        "2006 LTIP Units" means the units of the class of
                        limited partnership interest initially issued on April
                        4, 2006, having the rights, powers, privileges,
                        restrictions, qualifications and limitations set forth
                        in the Supplement to the Partnership Agreement dated as
                        of such date.

                  (b) Section 6.1E of the Partnership Agreement is hereby
amended by replacing the text thereof with the following:

                        E. Notwithstanding the provisions of Section 6.1.A
                        above, but subject to the prior allocation of income and
                        gain under clauses A(i), (ii) and (iii) above and to the
                        terms of any Partnership Unit Designation in respect of
                        any class of Partnership Interests ranking senior to the
                        LTIP Units, the 2005 LTIP Units and the 2006 LTIP Units
                        with respect to return of capital or any preferential or
                        priority return, any Liquidating Capital Gains shall
                        first be allocated to the holders of LTIP Units and next
                        to holders of 2005 LTIP Units and next to holders of
                        2006 LTIP Units until the Economic Capital Account
                        Balances of such holders, to the extent attributable to
                        their ownership of LTIP Units, 2005 LTIP Units or 2006
                        LTIP Units, as applicable, are equal to (i) the Common
                        Unit Economic Balance, multiplied by (ii) the number of
                        their LTIP Units, 2005 LTIP Units or 2006 LTIP Units, as
                        applicable; provided that no such Liquidating Capital
                        Gains will be allocated with respect to any particular
                        LTIP Unit, 2005 LTIP Unit or 2006 LTIP Unit, as
                        applicable, unless and to the extent that the Common
                        Unit Economic Balance exceeds the Common Unit Economic
                        Balance in existence at the time such LTIP Unit, 2005
                        LTIP Unit or 2006 LTIP Unit, as applicable, was issued.
                        For this purpose, "Liquidating Capital Gains" means net
                        capital gains realized in connection with the actual or
                        hypothetical sale of all or substantially all of the
                        assets of the Partnership, including but not limited to
                        net capital gain realized in connection with an
                        adjustment to the Carrying Value of Partnership assets
                        under Section 704(b) of the Code. The "Economic Capital
                        Account Balances" of the holders of LTIP Units, 2005
                        LTIP Units or 2006 LTIP Units, as applicable, will be
                        equal to their Capital Account balances, plus the amount
                        of their shares of any Partner Minimum Gain or
                        Partnership Minimum Gain, in either case to the extent
                        attributable to their ownership of LTIP Units, 2005 LTIP
                        Units or 2006 LTIP Units, as applicable. Similarly, the
                        "Common Unit Economic Balance" shall mean (i) the
                        Capital Account Balance of the Company, plus the amount
                        of the Company's share of any Partner Minimum Gain or
                        Partnership Minimum Gain, in either case to the extent
                        attributable to the Company's ownership of Common Units
                        and computed on a hypothetical basis after taking into
                        account all allocations through the date on which any
                        allocation is made under this Section 6.1.E, divided by
                        (ii) the number of the Company's Common Units. Any such
                        allocations shall be made first among the LTIP
                        Unitholders, next among the 2005 LTIP Unitholders and
                        next among the 2006 LTIP Unitholders in proportion to
                        the amounts required to be allocated to each under this
                        Section 6.1.E. The parties agree that the intent of this
                        Section 6.1.E is to make the Capital Account Balance
                        associated with each LTIP Unit, 2005 LTIP Unit and 2006
                        LTIP Unit economically equivalent to the Capital Account
                        Balance associated with the Company's Common Units (on a
                        per-Unit basis), but only if the Capital Account Balance
                        associated with the Company's Common Units has increased
                        on a per-Unit basis since the issuance of the relevant
                        LTIP Unit, 2005 LTIP Unit or 2006 LTIP Unit, as
                        applicable.

                                       2
<PAGE>

                  (c) Section 8.6A is hereby amended by replacing the text of
the final sentence thereof with the following:

                        Notwithstanding the foregoing, the Redemption Right
                        shall not be exercisable with respect to any Common Unit
                        issued upon conversion of an LTIP Unit, a 2005 LTIP Unit
                        or a 2006 LTIP Unit, as applicable, until on or after
                        the date that is two years after the date on which the
                        LTIP Unit, 2005 LTIP Unit or 2006 LTIP Unit, as
                        applicable, was issued, provided however, that the
                        foregoing restriction shall not apply if the Redemption
                        Right is exercised by an LTIP Unitholder, a 2005 LTIP
                        Unitholder or a 2006 LTIP Unitholder, as applicable, in
                        connection with a transaction that falls within the
                        definition of a "change-in-control" under the agreement
                        or agreements to which the LTIP Units, the 2005 LTIP
                        Units or the 2006 LTIP Units, as applicable, were issued
                        to him or her.

                  (d) The term "transfer" as used in Article 11 of the
Partnership Agreement shall not include any conversion of 2006 LTIP Units into
Common Units.

SECTION 3.        Continuation of Partnership Agreement.

                  The Partnership Agreement and this Supplement shall be read
together and shall have the same force and effect as if the provisions of the
Partnership Agreement and this Supplement (including EXHIBIT I hereto) were
contained in one document. Any provisions of the Partnership Agreement not
amended by this Supplement shall remain in full force and effect as provided in
the Partnership Agreement immediately prior to the date hereof.

                                       3
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Supplement to
the Partnership Agreement as of the 4th day of April, 2006.

                           GENERAL PARTNER:

                           RECKSON ASSOCIATES REALTY CORP.

                           By:  /s/ Jason Barnett
                                -----------------
                                Name: Jason Barnett
                                Title: Senior Executive Vice President-Corporate
                                         Initiatives and General Counsel

                           EXISTING LIMITED PARTNERS:

                           By: Reckson Associates Realty Corp.,
                                 as Attorney-in-Fact for the Limited Partners

                           By:  /s/ Jason Barnett
                                -----------------
                                Name: Jason Barnett
                                Title: Senior Executive Vice President-Corporate
                                         Initiatives and General Counsel

                           GRANTEES:

                           *Individual Counterpart Signature Pages Attached.

                                       4
<PAGE>

                       RECKSON OPERATING PARTNERSHIP, L.P.

                         Limited Partner Signature Page

         The undersigned, desiring to become one of the within named Limited
Partners of Reckson Operating Partnership, L.P. (the "Partnership") hereby
becomes a party to the Amended and Restated Agreement of Limited Partnership,
dated as of June 2, 1995 and amended through the date hereof, of the
Partnership, by and among Reckson Associates Realty Corp. and such Limited
Partners. The undersigned agrees that this signature page may be attached to any
counterpart of said Amended and Restated Agreement of Limited Partnership.

Date:
                                       ----------------------------------------
                                       Name of Limited Partner (please print)

                                       ----------------------------------------
                                       Signature

                                       ----------------------------------------
                                       Address

<PAGE>

                                    EXHIBIT I

                       RECKSON OPERATING PARTNERSHIP, L.P.

                 DESIGNATION OF THE RIGHTS, POWERS, PRIVILEGES,
                  RESTRICTIONS, QUALIFICATIONS AND LIMITATIONS
                             OF THE 2006 LTIP UNITS

         The following are the terms of the 2006 LTIP Units established pursuant
to this Supplement:

         1. Number. The maximum number of authorized LTIP Units shall be
207,000, subject to adjustment as provided herein.

         2. Vesting.

            (a) Vesting, Generally. LTIP Units may, in the sole discretion of
the General Partner, be issued subject to vesting, forfeiture and additional
restrictions on transfer pursuant to the terms of an award vesting or other
similar agreement (a "Vesting Agreement"). The terms of any Vesting Agreement
may be modified by the General Partner from time to time in its sole discretion,
subject to any restrictions on amendment imposed by the relevant Vesting
Agreement or by the terms of any plan pursuant to which the 2006 LTIP Units are
issued, if applicable. 2006 LTIP Units that have vested under the terms of a
Vesting Agreement are referred to as "Vested 2006 LTIP Units"; all other 2006
LTIP Units shall be treated as "Unvested 2006 LTIP Units." Subject to the terms
of any Vesting Agreement, a holder of 2006 LTIP Units shall be entitled to
transfer his or her 2006 LTIP Units to the same extent, and subject to the same
restrictions as holders of Common Units are entitled to transfer their Common
Units pursuant to Article 11 of the Agreement.

            (b) Forfeiture or Transfer of Unvested 2006 LTIP Units. Unless
otherwise specified in the Vesting Agreement, upon the occurrence of any event
specified in a Vesting Agreement as resulting in either the right of the
Partnership or the Company to repurchase 2006 LTIP Units at a specified purchase
price or some other forfeiture of any 2006 LTIP Units, then if the Partnership
or the Company exercises such right to repurchase or upon the occurrence of the
circumstances resulting in such forfeiture, then the relevant 2006 LTIP Units
shall immediately, and without any further action, be treated as transferred to
the Company, if applicable, or cancelled and no longer outstanding for any
purpose. Unless otherwise specified in the Vesting Agreement, no consideration
or other payment shall be due with respect to any 2006 LTIP Units that have been
forfeited, other than any distributions declared with respect to a Distribution
Payment Record Date (as defined below) prior to the effective date of the
forfeiture. In connection with any repurchase or forfeiture of 2006 LTIP Units,
the balance of the portion of the Capital Account of the holder that is
attributable to all of his or her 2006 LTIP Units shall be reduced by the
amount, if any, by which it exceeds the target balance contemplated by Section
6.1.E of the Partnership Agreement, calculated with respect to the Holder's
remaining 2006 LTIP Units, if any.

                                    Exh. I-1
<PAGE>

(c) Legend. Any certificate evidencing a 2006 LTIP Unit shall bear an
appropriate legend indicating that additional terms, conditions and restrictions
on transfer, including without limitation any Vesting Agreement, apply to the
2006 LTIP Unit.

         3. Distributions.

            (a) 2006 LTIP Distribution Amount. Commencing as of the quarterly
period beginning on April 1, 2006, for any quarterly period holders of such 2006
LTIP Units shall be entitled to receive, if, when and as authorized by the
General Partner out of funds legally available for the payment of distributions,
cash distributions in an amount per unit equal to the distribution payable on
the Common Units for the corresponding quarterly period (the "2006 LTIP
Distribution Amount"). Distributions on the 2006 LTIP Units, if authorized,
shall be payable quarterly in arrears on such dates as may be authorized by the
General Partner (any such date, a "Distribution Payment Date"). In addition,
2006 LTIP Units shall be entitled to receive, if, when and as authorized by the
General Partner out of funds or other property legally available for the payment
of distributions, any special, extraordinary or other distributions payable on
the Common Units which may be made from time to time in an amount per unit equal
to the amount of any special, extraordinary or other distributions payable on
the Common Units. Distributions will be payable to the holder of the 2006 LTIP
Units with respect to the 2006 LTIP Units held at the close of business on the
applicable record date, which shall be such date designated by the General
Partner for the payment of distributions that is not more than 30 nor less than
10 days prior to such Distribution Payment Date (each, a "Distribution Payment
Record Date"). With regard to any distribution to the 2006 LTIP Units, the
Distribution Payment Date shall be the same date as the date fixed for the
payment of distributions to holders of Common Units and the Distribution Payment
Record Date shall be the same date set for the record date for holders of Common
Units. In the event that distributions to holders of Common Units for any period
are paid on other than a quarterly basis, for example, on a monthly basis, then
distributions to holders of the 2006 LTIP Units shall also be paid on that
alternate basis.

            (b) Prohibited Distributions. No distributions on the 2006 LTIP
Units shall be authorized by the General Partner or be paid or set apart for
payment by the Partnership at such time as the terms and provisions of any
agreement of the Partnership, including any agreement relating to its
indebtedness, prohibits such authorization, payment or setting apart for payment
or provides that such authorization, payment or setting apart for payment would
constitute a breach thereof or a default thereunder, or if such authorization or
payment shall be restricted or prohibited by law.

            (c) Noncumulative Distributions. Distributions on the 2006 LTIP
Units will be noncumulative. If the General Partner does not authorize a
distribution on the 2006 LTIP Units payable on any Distribution Payment Date
while any 2006 LTIP Unit is outstanding, then the holder of the 2006 LTIP Units
will have no right to receive a distribution for that Distribution Payment Date,
and the Partnership will have no obligation to pay a distribution for that
Distribution Payment Date with respect to the 2006 LTIP Units.

                                    Exh. I-2
<PAGE>

            (d) Parity with Common Units. No distributions, whether in cash,
securities or property, will be authorized or paid or set apart for payment to
holders of Common Units for any period unless for each 2006 LTIP Unit
outstanding, a distribution equal to the 2006 LTIP Distribution Amount with
respect to such period has been or contemporaneously is authorized and paid or
authorized and a sum sufficient for the payment thereof is set apart for such
payment to the holders of the 2006 LTIP Units for such distribution period.

            (e) Definition of Set Apart for Payment. As used in this Section 3,
"set apart for payment" shall be deemed to include, without any further action,
the following: the recording by the Partnership in its accounting ledgers of any
accounting or bookkeeping entry which indicates, pursuant to an authorization of
a distribution by the General Partner, the allocation of funds to be so paid on
any series or class of units of the Partnership.

         4. Adjustments.

                  The Partnership shall maintain at all times a one-to-one
correspondence between 2006 LTIP Units and Common Units for conversion,
distribution and other purposes, including without limitation complying with the
following procedures. If an Adjustment Event (as defined below) occurs, then the
General Partner shall make a corresponding adjustment to the 2006 LTIP Units to
maintain a one-for-one conversion and economic equivalence ratio between Common
Units and 2006 LTIP Units. The following shall be "Adjustment Events": (A) the
Partnership makes a distribution on all outstanding Common Units in Partnership
Units, (B) the Partnership subdivides the outstanding Common Units into a
greater number of units or combines the outstanding Common Units into a smaller
number of units, or (C) the Partnership issues any Partnership Units in exchange
for its outstanding Common Units by way of a reclassification or
recapitalization of its Common Units. If more than one Adjustment Event occurs,
the adjustment to the 2006 LTIP Units need be made only once using a single
formula that takes into account each and every Adjustment Event as if all
Adjustment Events occurred simultaneously. For the avoidance of doubt, the
following shall not be Adjustment Events: (x) the issuance of Partnership Units
in a financing, reorganization, acquisition or other similar business
transaction, (y) the issuance of Partnership Units pursuant to any employee
benefit or compensation plan or distribution reinvestment plan, or (z) the
issuance of any Partnership Units to the Company in respect of a capital
contribution to the Partnership of proceeds from the sale of securities by the
Company. If the Partnership takes an action affecting the Common Units other
than actions specifically described above as "Adjustment Events" and in the
opinion of the General Partner such action would require an adjustment to the
2006 LTIP Units to maintain the one-to-one correspondence described above, the
General Partner shall have the right to make such adjustment to the 2006 LTIP
Units, to the extent permitted by law and by the terms of any plan pursuant to
which the 2006 LTIP Units have been issued, in such manner and at such time as
the General Partner, in its sole discretion, may determine to be appropriate
under the circumstances. If an adjustment is made to the 2006 LTIP Units as
herein provided the Partnership shall promptly file in the books and records of
the Partnership an officer's certificate setting forth such adjustment and a
brief statement of the facts requiring such adjustment, which certificate shall
be conclusive evidence of the correctness of such adjustment absent manifest
error. Promptly after filing of such certificate, the Partnership shall mail a
notice to each holder of 2006 LTIP Units setting forth the adjustment to his or
her 2006 LTIP Units and the effective date of such adjustment.

                                    Exh. I-3
<PAGE>

         5. Ranking.

            The 2006 LTIP Units shall rank on parity with the Common Units in
all respects.

         6. No Liquidation Preference.

            The 2006 LTIP Units shall have no liquidation preference.

         7. Right to Convert 2006 LTIP Units into Common Units.

            (a) Conversion Right. On or after the date that is two (2) years
after the 2006 LTIP Issuance Date a holder of 2006 LTIP Units shall have the
right (the "Conversion Right"), at his or her option, at any time to convert all
or a portion of his or her Vested 2006 LTIP Units into Common Units; provided,
however, that a holder may not exercise the Conversion Right for fewer than one
thousand (1,000) Vested 2006 LTIP Units or, if such holder holds fewer than one
thousand Vested 2006 LTIP Units, all of the holder's Vested 2006 LTIP Units.
Holders of 2006 LTIP Units shall not have the right to convert Unvested 2006
LTIP Units into Common Units until they become Vested 2006 LTIP Units. The
General Partner shall have the right at any time to cause a conversion of Vested
2006 LTIP Units into Common Units. In all cases, the conversion of any 2006 LTIP
Units into Common Units shall be subject to the conditions and procedures set
forth in this Section 7.

            (b) Number of Units Convertible. A holder of Vested 2006 LTIP Units
may convert such Units into an equal number of fully paid and non-assessable
Common Units, giving effect to all adjustments (if any) made pursuant to Section
4. Notwithstanding the foregoing, in no event may a holder of Vested 2006 LTIP
Units convert a number of Vested 2006 LTIP Units that exceeds (x) the Economic
Capital Account Balance of such holder, to the extent attributable to its
ownership of 2006 LTIP Units, divided by (y) the Common Unit Economic Balance,
in each case as determined as of the effective date of conversion (the "Capital
Account Limitation").

            (c) Notice. In order to exercise his or her Conversion Right, a
holder of 2006 LTIP Units shall deliver a notice (a "Conversion Notice") in the
form attached as EXHIBIT A to this Supplement (with a copy to the General
Partner) not less than 10 nor more than 60 days prior to a date (the "Conversion
Date") specified in such Conversion Notice; provided, however, that if the
General Partner has not given to the 2006 LTIP Unitholders notice of a proposed
or upcoming Transaction (as defined below) at least thirty (30) days prior to
the effective date of such Transaction, then holders of 2006 LTIP Units shall
have the right to deliver a Conversion Notice until the earlier of (x) the tenth
(10th) day after such notice from the General Partner of a Transaction or (y)
the third business day immediately preceding the effective date of such
Transaction. A Conversion Notice shall be provided in the manner provided in
Section 15.1 of the Partnership Agreement. Each Holder of 2006 LTIP Units
covenants and agrees with the Partnership that all Vested 2006 LTIP Units to be
converted pursuant to this Section 7 shall be free and clear of all liens.
Notwithstanding anything herein to the contrary, a Holder of 2006 LTIP Units may
deliver a Redemption Notice pursuant to Section 8.6 of the Partnership Agreement
relating to those Common Units that will be issued to such holder upon
conversion of such 2006 LTIP Units into Common Units in advance of the
Conversion Date; provided, however, that the redemption of such Common Units by
the Partnership shall in no event take place until the Conversion Date. For
clarity, it is noted that the objective of this paragraph is to put a holder of
2006 LTIP Units in a position where, if he or she so wishes, the Common Units
into which his or her Vested 2006 LTIP Units will be converted can be redeemed
by the Partnership simultaneously with such conversion, with the further
consequence that, if the Company elects to assume the Partnership's redemption
obligation with respect to such Common Units under Section 8.6 of the
Partnership Agreement by delivering to such holder REIT Shares rather than cash,
then such holder can have such REIT Shares issued to him or her simultaneously
with the conversion of his or her Vested 2006 LTIP Units into Common Units. The
General Partner shall cooperate with a holder of 2006 LTIP Units to coordinate
the timing of the different events described in the foregoing sentence.

                                    Exh. I-4
<PAGE>

            (d) Forced Conversion. The Partnership, at any time at the election
of the General Partner, may cause any number of Vested 2006 LTIP Units held by a
holder of 2006 LTIP Units to be converted (a "Forced Conversion") into an equal
number of Common Units, giving effect to all adjustments (if any) made pursuant
to Section 4; provided, that the Partnership may not cause a Forced Conversion
of any 2006 LTIP Units that would not at the time be eligible for conversion at
the option of such 2006 LTIP Unitholder pursuant to paragraph (b) above. In
order to exercise its right of Forced Conversion, the Partnership shall deliver
a notice (a "Forced Conversion Notice") in the form attached as EXHIBIT B to
this Supplement to the applicable Holder not less than 10 nor more than 60 days
prior to the Conversion Date specified in such Forced Conversion Notice. A
Forced Conversion Notice shall be provided in the manner provided in Section
15.1 of the Partnership Agreement.

            (e) Conversion Procedures. A conversion of Vested 2006 LTIP Units
for which the Holder has given a Conversion Notice or the Partnership has given
a Forced Conversion Notice shall occur automatically after the close of business
on the applicable Conversion Date without any action on the part of such holder
of 2006 LTIP Units, as of which time such holder of 2006 LTIP Units shall be
credited on the books and records of the Partnership with the issuance as of the
opening of business on the next day of the number of Common Units issuable upon
such conversion. After the conversion of 2006 LTIP Units as aforesaid, the
Partnership shall deliver to such holder of 2006 LTIP Units, upon his or her
written request, a certificate of the General Partner certifying the number of
Common Units and remaining 2006 LTIP Units, if any, held by such Person
immediately after such conversion.

                                    Exh. I-5
<PAGE>

            (f) Treatment of Capital Account. For purposes of making future
allocations under Section 6.1.E of the Agreement and applying the Capital
Account Limitation, the portion of the Economic Capital Account Balance of the
applicable holder of 2006 LTIP Units that is treated as attributable to his or
her 2006 LTIP Units shall be reduced, as of the date of conversion, by the
product of the number of 2006 LTIP Units converted and the Common Unit Economic
Balance.

            (g) Mandatory Conversion in Connection with a Transaction. If the
Partnership or the General Partner shall be a party to any transaction
(including without limitation a merger, consolidation, unit exchange, self
tender offer for all or substantially all Common Units or other business
combination or reorganization, or sale of all or substantially all of the
Partnership's assets, but excluding any transaction which constitutes an
Adjustment Event), in each case as a result of which Common Units shall be
exchanged for or converted into the right, or the holders of such Units shall
otherwise be entitled, to receive cash, securities or other property or any
combination thereof (each of the foregoing being referred to herein as a
"Transaction"), then the General Partner shall, immediately prior to the
Transaction, exercise its right to cause a Forced Conversion with respect to the
maximum number of 2006 LTIP Units then eligible for conversion, taking into
account any allocations that occur in connection with the Transaction or that
would occur in connection with the Transaction if the assets of the Partnership
were sold at the Transaction price or, if applicable, at a value determined by
the General Partner in good faith using the value attributed to the Partnership
Units in the context of the Transaction (in which case the Conversion Date shall
be the effective date of the Transaction).

            In anticipation of such Forced Conversion and the consummation of
the Transaction, the Partnership shall use commercially reasonable efforts to
cause each holder of 2006 LTIP Units to be afforded the right to receive in
connection with such Transaction in consideration for the Common Units into
which his or her 2006 LTIP Units will be converted the same kind and amount of
cash, securities and other property (or any combination thereof) receivable upon
the consummation of such Transaction by a holder of the same number of Common
Units, assuming such holder of Common Units is not a Person with which the
Partnership consolidated or into which the Partnership merged or which merged
into the Partnership or to which such sale or transfer was made, as the case may
be (a "Constituent Person"), or an affiliate of a Constituent Person. In the
event that holders of Common Units have the opportunity to elect the form or
type of consideration to be received upon consummation of the Transaction, prior
to such Transaction the General Partner shall give prompt written notice to each
holder of 2006 LTIP Units of such election, and shall use commercially
reasonable efforts to afford such holders the right to elect, by written notice
to the General Partner, the form or type of consideration to be received upon
conversion of each 2006 LTIP Unit held by such holder into Common Units in
connection with such Transaction. If a holder of 2006 LTIP Units fails to make
such an election, such Holder (and any of its transferees) shall receive upon
conversion of each 2006 LTIP Unit held by him or her (or by any of his or her
transferees) the same kind and amount of consideration that a holder of a Common
Unit would receive if such Common Unit Holder failed to make such an election.

                                    Exh. I-6
<PAGE>

            Subject to the rights of the Partnership and the General Partner
under any Vesting Agreement and the terms of any plan under which 2006 LTIP
Units are issued, the Partnership shall use commercially reasonable effort to
cause the terms of any Transaction to be consistent with the provisions of this
Section 7 and to enter into an agreement with the successor or purchasing
entity, as the case may be, for the benefit of any holders of 2006 LTIP Units
whose 2006 LTIP Units will not be converted into Common Units in connection with
the Transaction that will (i) contain provisions enabling the holders of 2006
LTIP Units that remain outstanding after such Transaction to convert their 2006
LTIP Units into securities as comparable as reasonably possible under the
circumstances to the Common Units and (ii) preserve as far as reasonably
possible under the circumstances the distribution, special allocation,
conversion, and other rights set forth in the Partnership Agreement for the
benefit of the holders of 2006 LTIP Units.

         8.  Redemption at the Option of the Partnership.

             2006 LTIP Units will not be redeemable at the option of the
Partnership; provided, however, that the foregoing shall not prohibit the
Partnership from repurchasing 2006 LTIP Units from the holder thereof if and to
the extent such holder agrees to sell such 2006 LTIP Units.

         9.  Intentionally Omitted.

         10. Voting Rights.

             (a) Voting with Common Units. Holders of 2006 LTIP Units shall have
the right to vote on all matters submitted to a vote of the holders of Common
Units; holders of 2006 LTIP Units and Common Units shall vote together as a
single class, together with any other class or series of units of limited
partnership interest in the Partnership upon which like voting rights have been
conferred. In any matter in which the 2006 LTIP Units are entitled to vote,
including an action by written consent, each 2006 LTIP Unit shall be entitled to
one vote.

             (b) Special Approval Rights. In addition to, and not in limitation
of, the provisions of Section 10(a) above (and notwithstanding anything
appearing to be contrary in the Partnership Agreement), the Company and/or the
Partnership shall not, without the affirmative consent of the holders of
sixty-six and two-thirds percent (66 2/3%) of the then outstanding 2006 LTIP
Units, given in person or by proxy, either in writing or at a meeting, take any
action that would materially and adversely alter, change, modify or amend the
rights, powers or privileges of the 2006 LTIP Units; but subject in any event to
the following provisions: (i) no consent of the holders of 2006 LTIP Units will
be required if and to the extent that any such alteration, change, modification
or amendment would similarly alter, change, modify or amend the rights, powers
or privileges of the Common Units; (ii) with respect to the occurrence of any
merger, consolidation or other business combination or reorganization, so long
as the 2006 LTIP Units remain outstanding with the terms thereof materially
unchanged or, if the Partnership is not the surviving entity in such
transaction, are exchanged for a security of the surviving entity with terms
that are materially the same with respect to rights to allocations,
distributions, redemption, conversion and voting as the 2006 LTIP Units and
without any income, gain or loss expected to be recognized by the holder upon
the exchange for federal income tax purposes (and with the terms of the Common
Units or such other securities into which the 2006 LTIP Units (or the substitute
security therefor) are convertible materially the same with respect to rights to
allocations, distributions, redemption, conversion and voting), the occurrence
of any such event shall not be deemed to materially and adversely alter, change,
modify or amend the rights, powers or privileges of the 2006 LTIP Units; (iii)
any creation or issuance of any Common Units or of any class of series of common
or preferred units of the Partnership (whether ranking junior to, on a parity
with or senior to the 2006 LTIP Units with respect to payment of distributions,
redemption rights and the distribution of assets upon liquidation, dissolution
or winding up), which either (x) does not require the consent of the holders of
Common Units or (y) does require such consent and is authorized by a vote of the
holders of Common Units; and 2006 LTIP Units voting together as a single class,
together with any other class or series of units of limited partnership interest
in the Partnership upon which like voting rights have been conferred, shall not
be deemed to materially and adversely alter, change, modify or amend the rights,
powers or privileges of the 2006 LTIP Units; and (iv) any waiver by the
Partnership of restrictions or limitations applicable to any outstanding 2006
LTIP Units with respect to any holder or holders thereof shall not be deemed to
materially and adversely alter, change, modify or amend the rights, powers or
privileges of the 2006 LTIP Units with respect to other holders. The foregoing
voting provisions will not apply if, as of or prior to the time when the action
with respect to which such vote would otherwise be required will be taken or be
effective, all outstanding 2006 LTIP Units shall have been converted, or
provision is made for such conversion to occur as of or prior to such time.

                                    Exh. I-7
<PAGE>

                                    Exhibit A

                    NOTICE OF ELECTION BY PARTNER TO CONVERT
                        2006 LTIP UNITS INTO COMMON UNITS

         The undersigned holder of 2006 LTIP Units hereby irrevocably elects to
convert the number of Vested 2006 LTIP Units in Reckson Operating Partnership,
L.P. (the "Partnership") set forth below into Common Units in accordance with
the terms of the Amended and Restated Agreement of Limited Partnership of the
Partnership, as amended. The undersigned hereby represents, warrants, and
certifies that the undersigned: (a) has title to such 2006 LTIP Units, free and
clear of the rights or interests of any other person or entity other than the
Partnership; (b) has the full right, power, and authority to cause the
conversion of such 2006 LTIP Units as provided herein; and (c) has obtained the
consent or approval of all persons or entities, if any, having the right to
consent or approve such conversion.

Name of Holder:
                ----------------------------------------------------------------
                (Please Print: Exact Name as Registered with Partnership)

Number of 2006 LTIP Units to be Converted:
                                            ------------------------------------

Date of this Notice:
                    ------------------------------------------------------------

         -----------------------------------------------------------------------
         (Signature of Holder: Sign Exact Name as Registered with Partnership)

         -----------------------------------------------------------------------
         (Street Address)

         -----------------------------------------------------------------------
         (City) (State) (Zip Code)

         Signature Guaranteed by:
                                 -----------------------------------------------

                                     Exh. A
<PAGE>

                                    Exhibit B

              NOTICE OF ELECTION BY PARTNERSHIP TO FORCE CONVERSION
                      OF 2006 LTIP UNITS INTO COMMON UNITS

         Reckson Operating Partnership, L.P. (the "Partnership") hereby
irrevocably elects to cause the number of 2006 LTIP Units held by the holder of
2006 LTIP Units set forth below to be converted into Common Units in accordance
with the terms of the Amended and Restated Agreement of Limited Partnership of
the Partnership.

Name of Holder:
                ----------------------------------------------------------------
                (Please Print: Exact Name as Registered with Partnership)

Number of 2006 LTIP Units to be Converted:
                                          --------------------------------------

Date of this Notice:
                    ------------------------------------------------------------

                                     Exh. B
<PAGE>

                                   Schedule A

<TABLE>
<CAPTION>

                     Name and Address                                Number of 2006 LTIP Units
                     ----------------                                -------------------------
<S>                                                                  <C>
Scott H. Rechler                                                              100,000
c/o Reckson Associates Realty Corp.
225 Broadhollow Road
Melville, New York 11747

Michael Maturo                                                                50,000
c/o Reckson Associates Realty Corp.
225 Broadhollow Road
Melville, New York 11747

Jason M. Barnett                                                              15,000
c/o Reckson Associates Realty Corp.
225 Broadhollow Road
Melville, New York 11747

Salvatore Campofranco                                                         10,000
c/o Reckson Associates Realty Corp.
225 Broadhollow Road
Melville, New York 11747

F. D. Rich                                                                    12,500
c/o Reckson Associates Realty Corp.
225 Broadhollow Road
Melville, New York 11747

Philip Waterman                                                                2,500
c/o Reckson Associates Realty Corp.
225 Broadhollow Road
Melville, New York 11747

Todd Rechler                                                                   8,500
c/o Reckson Associates Realty Corp.
225 Broadhollow Road
Melville, New York 11747

Richard Conniff                                                                8,500
c/o Reckson Associates Realty Corp.
225 Broadhollow Road
Melville, New York 11747
</TABLE>

                                     Sch. A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]